Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER 1009: Dacomitinib vs Erlotinib in Advanced NSCLC
NCT01360554Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2011
- Primary completion
- Sep 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 3 trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jun 2011; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01360554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360554.